(Q34173253)

31 July 2017

1 reference

title

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway (English)

1 reference

31 July 2017

1 reference

C Evangelisti

2

0 references

Marco Donia

object named as

M Donia

7

0 references

Paolo Fagone

object named as

P Fagone

8

0 references

Massimo Libra

object named as

M Libra

10

0 references

Ferdinando Nicoletti

1 reference

ORCID Public Data File 2021

author name string

A M Martelli

1

1 reference

31 July 2017

W Chappell

3

1 reference

31 July 2017

S L Abrams

4

1 reference

31 July 2017

J Bäsecke

5

1 reference

31 July 2017

F Stivala

6

1 reference

31 July 2017

F Nicoletti

9

1 reference

31 July 2017

V Ruvolo

11

1 reference

31 July 2017

P Ruvolo

12

1 reference

31 July 2017

C R Kempf

13

1 reference

31 July 2017

L S Steelman

14

1 reference

31 July 2017

J A McCubrey

15

1 reference

31 July 2017

publication date

25 March 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

25

1 reference

31 July 2017

issue

7

1 reference

31 July 2017

page(s)

1064-1079

1 reference

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Thymic lymphoma induction by the AKT8 murine retrovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

CREB is a regulatory target for the protein kinase Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Induction of NF-kappaB by the Akt/PKB kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Forkhead transcription factors are targets of signalling by the proto-oncogene PKB (C-AKT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

PTEN and the PI3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The role of PTEN signaling perturbations in cancer and in targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Tenets of PTEN tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The lipid phosphatase activity of PTEN is critical for its tumor supressor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

PTEN/MMAC1/TEP1 involvement in primary prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Non-genomic loss of PTEN function in cancer: not in my genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Subtle variations in Pten dose determine cancer susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

A microRNA polycistron as a potential human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Pathological and molecular aspects of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Genomic targets of the human c-Myc protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

MYCN regulates oncogenic MicroRNAs in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Transcribed processed pseudogenes in the human genome: an intermediate form of expressed retrosequence lacking protein-coding ability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

A coding-independent function of gene and pseudogene mRNAs regulates tumour biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

SALL4 is a key regulator of survival and apoptosis in human leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Relevant mouse model for human monocytic leukemia through Cre/lox-controlled myeloid-specific deletion of PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

p53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Post-translational regulation of PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

PTEN is destabilized by phosphorylation on Thr366.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Rak functions as a tumor suppressor by regulating PTEN protein stability and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement of SHIP-2 in negative signalling of B-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

mTOR integrates amino acid- and energy-sensing pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The role of Bcl-2 family proteins in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The Bcl-2 family as a rational target for the treatment of B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

AH/PH domain-mediated interaction between Akt molecules and its potential role in Akt regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Controlling the cell death mediators Bax and Bak: puzzles and conundrums

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The emerging roles of forkhead box (Fox) proteins in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Bone marrow microenvironment and the identification of new targets for myeloma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Drug resistance in mutant FLT3-positive AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

JNK/SAPK mediates doxorubicin-induced differentiation and apoptosis in MCF-7 breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Bim-targeted cancer therapy: a link between drug action and underlying molecular changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Targeting translation in acute myeloid leukemia: a new paradigm for therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Further evidence that ribavirin interacts with eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Predicted mechanisms of resistance to mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Determinants of rapamycin sensitivity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Targeting the eukaryotic translation initiation factor 4E for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

New modes of translational control in development, behavior, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Translational control and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Altering chemosensitivity by modulating translation elongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

mTORC1 promotes survival through translational control of Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Syk-dependent mTOR activation in follicular lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Tumorigenic activity and therapeutic inhibition of Rheb GTPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

HIF-1-regulated glucose metabolism: a key to apoptosis resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Hypoxia and HIF-1alpha protect A549 cells from drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Antisense HIF-1alpha prevents acquired tumor resistance to angiostatin gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Suppression of leukemia development caused by PTEN loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Identification of cancer stem cells in a Tax-transgenic (Tax-Tg) mouse model of adult T-cell leukemia/lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Foxo3a is essential for maintenance of the hematopoietic stem cell pool.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

PML targeting eradicates quiescent leukaemia-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

PTEN Autoregulates Its Expression by Stabilization of p53 in a Phosphatase-Independent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

7 January 2021

A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

7 January 2021

Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

7 January 2021

Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

7 January 2021

Regulatory phosphorylation of Bim: sorting out the ERK from the JNK

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

7 January 2021

Constitutive phosphorylation of FKHR transcription factor as a prognostic variable in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

7 January 2021

Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

7 January 2021

Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

7 January 2021

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.46

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.46

1 reference

Dimensions Publication ID

31 July 2017

1033286363

0 references

1 reference